|
KMID : 1149120200170020027
|
|
Journal of the Korean Society for Psoriasis
2020 Volume.17 No. 2 p.27 ~ p.31
|
|
|
Psoriasis Treatment in the Era of COVID-19
|
|
Park Jin-Woo
Bang Chul-Hwan
|
|
|
Abstract
|
|
|
|
The recent outbreak of coronavirus disease 19 (COVID- 19), caused by the virus SARS-CoV-2, continues to increase. Most patients have showed mild symptoms, but some patients show fatal symptoms such as severe dyspnea, respiratory failure, septic shock, and multiple organ dysfunction or failure. The case fatality rate caused by COVID- 19 increases in patients with underlying disease, but data on the risk of COVID-19 in patients using immunosuppressants such as patients with psoriasis are still insufficient. Psoriasis is a chronic progressive inflammatory disease that occurs on the skin. It is accompanied by various metabolic syndromes, cardiovascular diseases, and autoimmune diseases, and uses various immunosuppressants and biologics for treatment. It is necessary to review the treatment of psoriasis in the era of COVID-19. This article is intended to provide a brief review of coronavirus and COVID-19, as well as a review of the association of COVID-19 infection with the use of cyclosporine, methotrexate, acitretin, and biologics, which are frequently used to treat the patients with psoriasis.
|
|
|
KEYWORD
|
|
|
Biologics, Coronavirus, COVID-19, Immunosuppressants, Psoriasis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|